Vulvovaginal Candida albicans infections: pathogenesis, immunity and vaccine prospects
- PMID: 25052208
- DOI: 10.1111/1471-0528.12994
Vulvovaginal Candida albicans infections: pathogenesis, immunity and vaccine prospects
Abstract
Although a number of fungal species belonging to the genus Candida can cause acute vulvovaginal infection (VVC), Candida albicans is by far the most prevalent etiological agent, particularly for the most severe chronic condition known as recurrent vulvovaginal candidiasis (RVVC). This review focuses on recent advances in pathogenic mechanisms and host immune responses to C. albicans and on the utilisation of this information in the development of a vaccine to prevent and/or treat vaginal candidiasis. Currently, two vaccines with main or sole RVVC as clinical indication have completed a phase 1 clinical trial, and one of them has entered a phase 2 trial.
Keywords: Candida albicans; immunity; pathogenesis; vaccines; vulvovaginal candidiasis.
© 2014 Royal College of Obstetricians and Gynaecologists.
References
-
- Eckert LO. Acute vulvovaginitis. N Engl J Med 2006;355:1244-52.
-
- Moreira D, Paula CR. Vulvovaginal candidiasis. Int J Gynaecol Obstet 2006;92:266-7.
-
- Ringdahl EN. Recurrent vulvovaginal candidiasis. Mol Med 2006;103:165-8.
-
- Sobel JD. Pathogenesis and treatment of recurrent vulvovaginal candidiasis. Clin Infect Dis 1992;14:S148-53.
-
- Bauters TG, Dhont MA, Temmerman MI, Nelis JH. Prevalence of vulvovaginal candidiasis and susceptibility to fluconazole in women. Am J Obstet Gynecol 2002;187:569-74.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
